PTH-134 Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the east midlands

PTH-134 Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the east midlands

IntroductionRandomised controlled trials have demonstrated efficacy of vedolizumab in Ulcerative Colitis (UC) and Crohn’s Disease (CD). Further data in the real-world setting is needed to inform future practice.MethodsA multicentre retrospective observational chart review study was conducted with al...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gut 2019-06, Vol.68 (Suppl 2), p.A102
Hauptverfasser: White, JR, Din, S, Ingram, R, Foley, S, Alam, M, Robinson, R, Francis, R, Tucker, E, Jalal, M, Elphick, D, Atallah, E, Norman, A, Amin, M, Sajjad, A, Heggs, N, Meadowcroft, S, Moran, GW
Format: Artikel
Sprache:eng
Schlagworte:
Biochemical markers
Clinical trials
Corticosteroids
Crohns disease
Inflammatory bowel disease
Inflammatory bowel diseases
Intestine
Monoclonal antibodies
Mucosa
Parathyroid hormone
Patients
Rectum
Remission
Tumor necrosis factor
Ulcerative colitis
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:IntroductionRandomised controlled trials have demonstrated efficacy of vedolizumab in Ulcerative Colitis (UC) and Crohn’s Disease (CD). Further data in the real-world setting is needed to inform future practice.MethodsA multicentre retrospective observational chart review study was conducted with all pts initiated on vedolizumab across 7 UK hospitals between 1/11/14–30/11/16. The Health Research Authority approved the protocol (19/HRA/0008). Clinical disease activity was assessed at baseline, week 14, 30 & 52 using the Harvey Bradshaw Index (HBI) and partial Mayo Score (pMS). Clinical remission was defined as HBI≤4 or pMS
ISSN:0017-5749
1468-3288
DOI:10.1136/gutjnl-2019-BSGAbstracts.193